Reetoo Biotech

CN EN

About Us

Founded in 2017, Reetoo Biotech is a trailblazer in innovative R&D, dedicated to the deep integration of artificial intelligence (AI) and morphology in the IVD field. As China’s first AI Medical Laboratory Innovation Center, it leads the industry’s transformation from automation to intelligent diagnostics. At Reetoo’s core is the next-generation DeepCell AI engine, powering a comprehensive product portfolio spanning hematology, urinalysis, feces analysis, sperm analysis, vaginal infection analysis and microbiology testing. As the only IVD manufacturer capable of providing end-to-end, fully automated, AI-powered morphology solutions for comprehensive specimen analysis, Reetoo enables intelligent diagnostics while enhancing accuracy and workflow standardization.

2017

Company Established
40%

R&D Staff Proportion
100+

Scientific Research Cooperation
600+

Patents
1500+

Trusted by Mid-to-Large Hospitals

History

2017-2018

2019-2020

2021-2022

2023-2024

2025

Our Beginning

2017-2018

Reetoo established
Initial core team formation
Began development of Gynecology System
Built a portfolio of five product lines
GMP factory construction

Forging Ahead

2019-2020

China's FIRST AI medical laboratory innovation center
Launched Vaginal secretion analyzer
6,000㎡ R&D center and production base
Successfully developed a portfolio of eight product lines
Scaled production with 12,000㎡ facility expansion

Gaining Momentum

2021-2022

Launched Urine analysis system
Vaginal secretion analyzer installed in 1000+ mid-to-large hospitals
Debuted at MEDICA and EUROMEDLAB

Rapid Scale & Expansion

2023-2024

Launched Vaginal microecology evaluation system
Launched Hematology automation line
Hematology automation line won the Red Dot Design Award
Obtained series B2 financing
Step in key countries such as Italy, Greece, Turkey, etc.

New Chapter: Global Reach

2025

Global installation 2500+ units
Installed the FIRST Vaginal microecology evaluation system in France’s Top-5 chain lab
Corporate member of the IFCC
Prix Galien Nominee-The ”Nobel Prize” of Biopharm

Production Capacity

Factory Area

Now, we have owned 14,000m ² R & D center and production base, including 1000m ² GMP factory.
Production Capacity

Annual analyzer capacity at 6,000 units, annual reagent capacity at 36 million tests.

Manufacture

Production Site Management

Implement strict 6S management
Visual factory management
Total productive maintenance (TPM)
Continuous improvement through Quality Control Circles (QCC)

Production Quality Management

Full compliance with medical device regulations & quality standards
China standard: GB-YY/T0287
EU IVD 98/79/EC
ISO 13485

Production Delivery Management

Integrated ERP system ensures company resources are efficiently aligned with customer demand.
End-to-end order tracking provides transparency and enables rapid, accurate delivery.

Supplier Management

ISO 16949-compliant supplier evaluation system
Robust supplier performance management

Business

Domestic Business Global Business

Marketing Network

Marketing service centers are located in 32 provinces and cities;
Installed Base

Entered into 1000+ large-scale hospitals in China, including some famous hospitals, like Wuhan Union Hospital of China

深圳总部

深圳总部

Address：深圳市宝安区华丰国际机器人产业园F栋406室

Tel：0755-86966760